Table 3 Clinical characteristics of the subjects used in the validation phase
Subject number | Age/gender | AHT | Diabetes | Dyslipidemia |
|---|---|---|---|---|
1 Control | 62/M | Yes | No | Yes |
2 Control | 82/M | Yes | No | No |
3 Control | 86/M | Yes | No | Yes |
4 Control | 96/M | No | Yes | Yes |
5 Control | 78/F | Yes | Yes | No |
6 Control | 81/M | Yes | No | No |
7 Control | 40/F | No | No | No |
8 Control | 30/M | No | No | No |
9 AS | 77/F | Yes | Yes | No |
10 AS | 86/M | Yes | No | No |
11 AS | 69/F | Yes | No | No |
12 AS | 77/M | No | No | No |
13 AS | 60/F | Yes | No | No |
14 AS | 75/F | Yes | No | Yes |
15 AS | 74/M | No | No | Yes |
16 AS | 74/F | Yes | Yes | No |
Mean control | 75% M | 62.75% | 25% | 37.75% |
Mean AS | 37.5% M | 75 | 25% | 25% |